|
Characteristics
|
Value
|
|---|
|
Age (years)
|
Mean (SD)
|
52.2 (10.6)
|
|
Sex
|
Male
|
1575 (85.3%)
|
|
Female
|
272 (14.7%)
|
|
HBV infection
|
No
|
242 (13.1%)
|
|
Yes
|
1605 (86.9%)
|
|
Cirrhosis
|
No
|
610 (33.0%)
|
|
Yes (compensated/decompensated)
|
1216 (65.9%)/21 (1.1%)
|
|
TBil (μmol/L)
|
Mean (SD)
|
14.6 (6.2)
|
|
Child-pugh
|
A
|
1751 (94.8%)
|
|
B
|
96 (5.2%)
|
|
AFP
|
≤400 ng/mL
|
1255 (67.9%)
|
| |
> 400 ng/mL
|
592 (32.1%)
|
|
γ-GT
|
≤54 U/L
|
947 (51.3%)
|
| |
> 54 U/L
|
900 (48.7%)
|
|
Transfusion
|
No
|
1739 (94.2%)
|
| |
Yes
|
108 (5.8%)
|
|
Tumor number
|
Single
|
1499 (81.2%)
|
| |
Multiple
|
348 (18.8%)
|
|
Tumor diameter (cm)
|
Mean (SD)
|
5.8 (3.8)
|
|
ES grading
|
I&II
|
172 (9.3%)
|
| |
III&IV
|
1675 (90.7%)
|
|
Capsule
|
Present
|
1487 (80.5%)
|
| |
Absent
|
360 (19.5%)
|
|
Satellite
|
No
|
1071 (58.0%)
|
| |
Yes
|
776 (42.0%)
|
|
MVI
|
Present
|
644 (34.9%)
|
| |
Absent
|
1203 (65.1%)
|
|
BCLC
|
0
|
107 (5.8%)
|
| |
A
|
1446 (78.3%)
|
| |
B
|
294 (15.9%)
|
|
AJCC
|
Ia
|
107 (5.8%)
|
| |
Ib
|
938 (50.8%)
|
| |
II
|
623 (33.7%)
|
| |
IIIa
|
179 (9.7%)
|
|
CNLC
|
Ia
|
846 (45.8%)
|
| |
Ib
|
707 (38.3%)
|
| |
IIa
|
203 (11.0%)
|
| |
IIb
|
91 (4.9%)
|
|
PA-TACE
|
No
|
1335 (72.3%)
|
| |
Yes
|
512 (27.7%)
|
- Note: HBV hepatitis B virus, TBil total bilirubin; AFP alpha-fetoprotein; γ-GT gamma-glutamyl transferase; ES Edmondson-Steiner; MVI microvascular invasion; PA-TACE postoperative adjuvant transarterial chemoembolization; AJCC according to the 8th American joint committee on cancer staging; CN CN staging was defined according the Chinese guideline for HCC
